Repligen

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Repligen (RGEN) reports strong 2022 performance, eyes growth amid challenges

Repligen anticipates a challenging yet optimistic year in 2023, with revenue guidance of $760-800 million and adjusted EPS of $2.61-2.69 per fully diluted share. The company remains focused on organic growth, innovation, and strategic acquisitions to navigate industry headwinds.

Repligen reports Q1 revenue growth, eyes China rebound and new products

Repligen's Q1 2023 performance saw revenue growth but overall revenues declined due to reduced COVID-related demand.
Despite challenges in China and revised guidance, strategic investments and confidence in future growth opportunities remain strong.
The company is focused on new product launches, pricing resilience, and addressing challenges to drive growth and margin improvement.

Repligen faces revenue decline and margin pressure, eyes growth strategies

Repligen faces challenges in revenue decline and margin compression but is focusing on cost control and new product launches for growth.
Diversified revenue streams and positive developments in orders and integration provide a foundation for future opportunities.
Market dynamics and pharma spend challenges pose uncertainties, but the company remains optimistic about growth prospects.
Visibility improvements, margin recovery expectations, and pricing strategies are key focus areas for future profitability.

Repligen sees recovery in Q3 amidst industry challenges and restructuring

Repligen's Q3 2023 showed signs of recovery amidst industry challenges, with a focus on cost optimization and new product launches. The company incurred restructuring charges to streamline operations and expects improved margins in 2024. Despite revenue declines, opportunities lie in the gene therapy segment and future recovery in China.

Repligen reports Q4 revenue decline but eyes growth in China

Repligen's Q4 2023 showed mixed results with revenue decline but sequential growth. The company is focusing on profitability improvements in 2024 and anticipates growth driven by new modalities and market recovery. Challenges in revenue performance are being addressed, with a strategic focus on key account management and cost containment.

Repligen reports mixed Q1 results, focuses on innovation and growth

Repligen's Q1 2024 performance showed mixed results with revenue declines but positive growth in key segments. The company maintains its focus on innovation, cost control, and strategic expansion while navigating challenges in profitability. Opportunities lie in market improvements and growth potential in new modalities.

Repligen reports strong Q2 performance, eyes robust growth ahead

Repligen's Q2 2024 earnings call showcased strong performance in pharma and consumables, despite challenges from China and foreign exchange. The company anticipates a return to robust revenue growth in the second half of the year and is optimistic about future growth prospects.

Repligen (RGEN) reports robust Q3 results and eyes 2025 growth

Repligen is on track to meet 2024 revenue guidance, entering 2025 in a strong position.
Exciting product launches planned for 2025 across all business units.
Strong start to Q4 with confidence in meeting financial targets.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

AAON

Cognex

In a low interest rate environment, acquisition targets in growth markets are likely to attract bidders.

These 3 Stocks Are Potential Buyout Targets

Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing Expands Single-Use Portfolio with Expertise in Silicone Molding and Tubing

Repligen Announces Agreement to Acquire Engineered Molding Technology

DexCom

JD.com

While many companies were unable to avoid the wrath of the coronavirus pandemic, these three companies stood out as big winners.

3 Great Growth Stocks That Kept Climbing in This Tough Market

WALTHAM, Mass., June  15, 2020  (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors. Ms. Eglinton Manner brings to the director role over 23 years of leadership experience across multiple disciplines. She currently serves as Senior Vice President, Advanced Diagnostics at Quest Diagnostics (NYSE:DGX), the world’s leading provider of diagnostic information services, which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare (NYSE:GE). From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue.

Repligen Appoints Carrie Eglinton Manner to Board of Directors

Quest Diagnostics

Fortinet

Okta

Here we pick four stocks that score as buying opportunities, despite their loss of value in the past week, on the back of strong fundamentals, prospects and optimism over a speedy U.S. economy revival.

Skip the Market Blip, Ride Next Rally With 4 Buy-Rated Picks

Grifols, S.A.

Johnson & Johnson

Merck

Dr. Reddy's Labs

Takeda Pharmaceutical

Zoetis

Much of the conversation about pharmaceutical stocks rests on the coronavirus, but these high-growth names have potential beyond the pandemic.

7 Pharmaceutical Stocks to Buy for Post-Pandemic Gains

Smart beta ETFs typically rebalance every 90 days. The next big rebalance will come in the next few weeks and likely push healthcare stock Repligen (RGEN) higher.

Repligen Stock Could See Significant Upside With Coming ETF Realignment

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Repligen (RGEN) Down 0.4% Since Last Earnings Report: Can It Rebound?

QIAGEN

QGEN vs. RGEN: Which Stock Is the Better Value Option?

BJ`s Wholesale Club Holdings Inc

SPS Commerce

Vertex Pharmaceuticals

Bet on five stocks that are likely to outdo earnings estimates.

Profit From 5 Stocks Likely to Beat on Earnings

Repligen (RGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Why Repligen (RGEN) Might be Well Poised for a Surge

The bioprocess equipment leader didn't see a slowdown from the coronavirus pandemic, while expected headwinds in a major business unit failed to materialize.

Repligen Bucks Industry Trend, Increases Full-Year 2020 Guidance

Repligen Corp. (RGEN) CEO Tony Hunt on Q1 2020 Results - Earnings Call Transcript

Repligen (NASDAQ: RGEN) shares are trading higher on Wednesday after the company reported better-than-expected first-quarter EPS and sales results.

Why Repligen's Stocks Is Trading Higher Today

The bioprocess leader relies on clinical trials for a significant portion of revenue. How disruptive will the coronavirus be?

Will Clinical Trial Delays Derail Repligen's Growth?

The bioprocess company was a rare bright spot for investors, although the worst is likely yet to come for the stock.

Here's Why Repligen Stock Gained 12.8% in March

Albemarle

These two stocks can be used to gauge how the pharmaceutical industry and energy sector are faring during the coronavirus pandemic -- and what might be ahead.

2 Top U.S. Stocks to Watch in April

Why Is Repligen (RGEN) Down 12.2% Since Last Earnings Report?

The biotechnology supplier ended a tough week with a bang.

Why Repligen Stock Jumped 10.6% On Friday

Drilling down in the numbers shows how the bioprocess leader became one of the best growth stocks on the market -- and how it remains well-positioned for long-term growth.

5 Numbers Repligen Investors Need to Know

WALTHAM, Mass., Feb.  27, 2020  (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of life sciences industry executive Rohin Mhatre, Ph.D., to its Board of Directors. Dr. Mhatre brings to the director role over 25 years of relevant experience, which includes his current position as Senior Vice President, Product and Technology Development for Biogen Inc., a leading multinational biopharmaceutical company. Dr. Mhatre leads a cross-functional department responsible for product and process development, process analytics and small-scale manufacturing. Most recently, he has also led the Engineering and Manufacturing Science departments. Throughout his career, he has evaluated and implemented cutting-edge production platforms and process analytical tools for a diverse array of therapeutics, including monoclonal antibodies, gene therapies and oligonucleotides, as well as small molecules.  “We are delighted to welcome Dr. Mhatre to our board,” said Karen A. Dawes, chairperson of the board of Repligen. “The relevance of Rohin’s experience to Repligen is clear. His skillsets and his passion for innovation underscore his success in driving progress in biopharmaceutical manufacturing, and we expect he will be a tremendous asset to the company.”  Tony J. Hunt, President and Chief Executive Officer said, “Rohin understands first-hand the drivers to improve manufacturing efficiency and yield, as biopharmaceutical manufacturing operations move towards flexible, single-use solutions and the drug pipeline diversifies beyond monoclonal antibodies. This will help us shape the future strategic direction for Repligen as we expand our products and applications."  Dr. Mhatre joined Biogen Inc. in 1996 and has held numerous roles of increasing responsibility leading to his current position of Senior Vice President, Product and Technology Development. Dr. Mhatre’s previous roles with Biogen include Vice President of Biopharmaceutical Development, where he led a 300-member team with responsibility for cell line, cell culture, purification, formulation and device development. Earlier in his career with Biogen, he was focused on building out analytical development and technical services, and prior to Biogen, he led the purification and applications group at Applied Biosystems (formerly Perseptive Biosystems). He received a Ph.D. in chemistry from Northeastern University.

Repligen Appoints Rohin Mhatre, Ph.D. to Board of Directors

Guidance for 2020 appears to have spooked investors, but the bioprocess leader is on a solid long-term trajectory.

Repligen Signals Gene Therapy Strength With 2019 Earnings Report

Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.

Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat

Repligen Corp. (RGEN) CEO Anthony Hunt on Q4 2019 Results - Earnings Call Transcript

Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

News for Repligen Stock (RGEN)